The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | HS-20122, an EGFR/cMET bispecific antibody-drug conjugate, in solid tumors
Hongyun Zhao, MD, Sun Yat-sen University Cancer Center, Guangzhou, China, discusses a first-in-human Phase I study (NCT06927570) of HS-20122, a novel EGFR/cMET bispecific antibody–drug conjugate (ADC) with a topoisomerase I inhibitor payload, in patients with advanced solid tumors, predominantly EGFR-mutant non-small cell lung cancer (NSCLC) previously treated with tyrosine kinase inhibitors. No dose-limiting toxicities were observed, adverse events were mainly hematologic, and target-related toxicities and interstitial lung disease were rare. Encouraging responses were seen in EGFR-mutant NSCLC and head and neck cancer, with efficacy signals in other solid tumors. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I just presented the phase one study results of HS-20122. It’s a novel HFR1 bispecific ADC, and it’s a big phase one study. We have the dose escalation and dose expansion part. The total population number is 215 patients. So we really see the HS2122 demonstrated the promising anti-tumor activity, especially in EGFR mutant non-small cell lung cancer and squamous non-small cell lung cancer and head and neck cancer...
I just presented the phase one study results of HS-20122. It’s a novel HFR1 bispecific ADC, and it’s a big phase one study. We have the dose escalation and dose expansion part. The total population number is 215 patients. So we really see the HS2122 demonstrated the promising anti-tumor activity, especially in EGFR mutant non-small cell lung cancer and squamous non-small cell lung cancer and head and neck cancer. For the IED dose level in six milligrams per kilo dose level, for patients pre-treated with EGFR TKI, the ORR was 61%. The six months PFS were 75%. So it’s very promising. And for patients with squamous non-small cell lung cancer and head and neck cancer, the ORR was there also promising. Squamous non-small cell lung cancer, the ORR was 32%. For head and neck cancer, including NPC, the ORR was 50%. So we think it’s good.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Yeah, it’s a good question because it’s a bi-specific ADC, so we pay more attention to on-target toxicity. But we compare with single EGFR ADC or MAT ADC, we have seen the most common grade 3 and above toxicity is hematological toxicity and could be manageable. And the data sheet is almost comparable with mono ADC. But for the HFR-targeted toxicity, for example, the diarrhea, the stomatitis, something like that is not very very high and could be manageable too.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
